Expect increased volatility and downside pressure due to aggressive regulatory focus on drug pricing and margin compression driven by the HHS Secretary.

The speaker's rhetoric suggests a pro-growth stance on the healthcare industry and medical innovation, potentially signaling policy support.

Considered an attractive defensive play with recovery potential after recently hitting its cheapest valuation on a relative basis in history. It may benefit as interest rates fall.